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Abbreviation List
AECOPD Acute exacerbation of chronic obstructive pulmonary disease
CAT COPD assessment test
COPD Chronic obstructive pulmonary disease
CRP C-reactive protein, serum
FEV1 Forced expiratory volume in 1 second
FVC Forced vital capacity




IMP Investigational medicinal product
LABA Long-acting ß-agonist
MRC Medical Research Council
NIHR National Institute of Health Research
RCT Randomised controlled trial
SGRQ St George’s Respiratory Questionnaire
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Abstract
Rationale
COPD exacerbations are prone to non-recovery but there are no data about the 
effectiveness of retreatment on these prolonged events. We examined whether 
further therapy with ciprofloxacin for incompletely resolved COPD exacerbations 
prolonged the time until the next event. 
Methods
This multi-centre randomised double-blind placebo-controlled trial studied 
retreatment with oral ciprofloxacin 500mg or matched placebo twice daily for 7 days 
in patients with GOLD stage II – IV COPD with persistent symptoms and/or serum C-
reactive protein (CRP) ≥8mg/L initiated 14 (+/- 3) days after an index COPD 
exacerbation. The primary outcome was the time to the next exacerbation within a 
90-day period. 
Results 
Of 826 patients screened at 4 centres, 144 eligible participants with incomplete 
recovery were randomised to receive ciprofloxacin (n=72) or placebo (n=72). Within 
90 days of randomization, 57% of patients in the ciprofloxacin group and 53% in the 
placebo group experienced 1 or more exacerbations. The median time to the next 
exacerbation was 32.5 days (IQR 13-50) in the placebo arm and 34 days (IQR 17-
62) in the ciprofloxacin arm, which was not significantly different (adjusted hazard 
ratio = 1.07, 95% CI 0.68-1.68; p=0.76). No significant differences were seen in 
quality of life scores or lung function between treatment groups.
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Conclusion
In patients with persistent symptoms and/or raised CRP 14 days following a COPD 
exacerbation, an additional course of ciprofloxacin resulted in no additional benefit 
compared to placebo.  This suggests that non-recovered exacerbations are not 
driven by ongoing bacterial infection and may potentially be targeted with anti-
inflammatory therapy.
Abstract word count: 248
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Introduction 
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are 
important events that have significant adverse consequences for patients (1). 
Frequent exacerbations are associated with accelerated lung function decline (2, 3), 
impaired quality of life (4) and increased mortality (5). There are also significant 
healthcare cost implications (6).
Exacerbations associated with sputum purulence or increased sputum volume are 
treated with antibiotics leading to faster resolution of the exacerbation and a longer 
time to the next AECOPD (7, 8). Despite antibiotic treatment, however, recovery is 
often delayed. More than one quarter of patients will experience another event 
during the following 8 weeks (9), whilst 25% do not recover to baseline by 5 weeks 
(10) and over one-third by three months (11). These recurrent events are associated 
with substantially increased mortality (11) and this has led to financial incentives for 
health care services aimed at avoiding hospital readmission (12, 13).
Previously we have reported that serum C-reactive protein (CRP) measured 14 days 
after an exacerbation was higher (mean=8.8 mg/dl) in patients experiencing another 
exacerbation within the next 50 days (recurrent exacerbation) than in those who did 
not (mean = 3.4 mg/dl) (14). A recent trial has demonstrated the utility of point-of-
care measurement of CRP at the onset of an AECOPD to target antibiotic treatment 
successfully, without negative effects on health status outcomes (15). At present, 
there are no studies assessing the efficacy of further antibiotic treatment for non-
recovery of an AECOPD. We therefore evaluated a novel treatment approach using 
point-of-care measurement of CRP and/or respiratory symptom review to guide 
antibiotic retreatment 14 days following an index exacerbation. Our aim was to 
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address whether retreatment at day 14 would prolong the time until the next 
exacerbation and hasten recovery of the index event.
Method
Study design
This study was a randomized parallel-group, double-blind placebo-controlled trial 
performed in 4 academic health centres in the UK. Patients were assessed for 
incomplete recovery at 14 +/- 3 days following the first day of antibiotic treatment for 
an AECOPD. Eligible patients were then randomised in a 1:1 ratio to receive oral 
ciprofloxacin 500mg or matched placebo twice daily for 7 days. Patients were 
instructed to continue their current COPD inhaled or oral treatment but if further oral 
corticosteroids or antibiotics other than the investigational medicinal product were 
clinically indicated at randomisation, then these individuals were excluded. Permuted 
block randomisation with stratification for site and current smoking status was used 
via an online portal (Sealed Envelope Ltd, London, UK).
The trial received approval from the National Research Ethics Committee, West 
Midlands - Edgbaston (13/WM/0364). All patients gave written informed consent. 
The trial was registered on EudraCT 2012-002198-72 and clinicaltrials.gov NCT 
02300220. 
Patients
Patients whose exacerbations were treated with antibiotics and/or systemic 
corticosteroids in accordance with Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) guidance (16) were screened for participation in this trial.  The main 
inclusion criteria were persistent symptoms and/or a serum CRP  8mg/L on day 14 
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following initial treatment. This CRP cut off was selected based on previous work 
from our group, examining the day 14 CRP in 73 AECOPD (14). Persistent 
symptoms were defined by any one or more of increased breathlessness, increased 
sputum volume or increased sputum colour compared to baseline. CRP was 
measured at the point of care using a Quikread Go CRP analyser (Orion 
Diagnostica, Helsinki, Finland). Eligible patients had an established diagnosis of 
GOLD stage II – IV COPD (based on clinical history and spirometry), were 45 years 
or older, and had a current or past smoking history of ≥10 pack-years. A full list of 
inclusion and exclusion criteria is provided in the Online Supplement.
Patients were followed for 90 days from randomization and underwent assessment 
visits on days 7 (visit 2), 28 (visit 3) and 90 (visit 4) after randomisation. Participants 
were asked to record worsening or new daily respiratory symptoms on diary cards 
and to self-report and attend for exacerbation visits if necessary (figure 1). New 
exacerbations during follow-up were assessed by the study physician based on the 
patient’s symptoms and treatment record on the diary card or when seen in clinic. An 
exacerbation was defined as an increase in respiratory symptoms for two 
consecutive days, with at least one major symptom (dyspnoea, sputum purulence or 
sputum volume) plus either another major or a minor symptom (wheeze, cold, sore 
throat and cough). The first day of these increased symptoms was defined as the 
day of onset of the exacerbation (10). The full trial protocol is available in the online 
data supplement.
At clinic visits post-bronchodilator spirometry was measured with a Flow Screen II 
spirometer (eResearchTechnology GmbH, Estenfeld, Germany) in accordance with 
ATS/ERS guidance (17). Blood samples were collected for measurement of CRP in 
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the hospital laboratory for longitudinal analysis of CRP during the study. Vital signs 
were recorded and respiratory symptoms assessed using the CAT questionnaire. At 
randomisation and at day 90, the St George’s Respiratory Questionnaire (SGRQ) 
was completed by the patient. Spontaneous sputum samples were obtained when 
possible and sent for routine bacterial culture; sputum induction was not performed.
Main efficacy outcomes
The primary outcome was the time from randomisation to the next exacerbation 
within a 90-day period. Pre-specified secondary outcomes included the duration of 
the initial exacerbation, change in CRP and health status (assessed by SGRQ and 
CAT questionnaire).
Sample size
The required sample size was calculated as 72 patients per group, 144 in total, in 
order to detect a difference in the primary endpoint at a two-sided significance level 
of 0.05 with 80% power. This is a novel study design, and in the absence of available 
prior data the power calculation was based on a survival analysis assuming 
proportional hazards with re-exacerbation within 90 days of 70% in the placebo arm 
and 45% in the treatment arm (hazard ratio [HR]=0.46). This sample size allowed for 
a drop-out rate of 5% and recruitment to target within the study centres.
Statistical Analysis
The primary endpoint was assessed using a Cox’s proportional hazard model with 
pre-specified adjustment for patient’s self-reported history of exacerbations over the 
previous year and with stratification for study centre. Survival data was censored at 
90 days or at patient withdrawal.  Patient demographics are reported as mean 
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(standard deviation), median (inter-quartile range) or as percentages. Differences in 
patient characteristics between sites were compared by ANOVA, Kruskal-Wallis or 
Chi-squared test as appropriate. Differences in the number of exacerbations during 
the 90 days of observation were assessed using a negative-binomial regression with 
adjustment for time under observation. CAT scores were analysed by random effect 
linear models to accommodate repeated measurements on the same patient. All 
analyses were performed using STATA 12.1 (STATA Corporation, College Station, 
TX, USA) and according to the principal of intention-to-treat. All statistical tests were 
two-sided and a p-value <0.05 considered significant. Apart from the primary 
outcome all statistical analyses should be considered as exploratory. 




Between July 2014 and November 2017, 826 patients with an AECOPD attending an 
emergency department or respiratory outpatient clinics were identified at the 4 
hospitals.  A total of 224 of these patients were screened at 14 days and 144 
randomized to either ciprofloxacin (n=72) or placebo (n=72) (figure 2). The most 
common reason for screening failure was recovery in symptoms of the index 
exacerbation (n=38 [17%]; see figure 2). Demographic and clinical characteristics of 
randomised subjects were well balanced across treatment arms (Table 1). There 
were no significant differences in adherence between groups; the median number of 
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treatment doses taken by patients was 14 (IQR 14-14) in the ciprofloxacin and 14 
(IQR 14-14) in the placebo arm (chi squared test, p=0.945). 
Clinical presentation
Of the 144 participants, 119 reported continuing symptoms of which there were 22 
type I, 34 type II and 63 type III Anthonisen criteria exacerbations based on symptom 
questionnaires recorded at randomisation (table 1). There was good balance 
between treatment arms. In addition to the 22 type I exacerbations, there were 19 
patients with persistent sputum purulence. 64 participants randomised had a positive 
CRP. Overall the mean CRP for included particpants was 15.3mg/L (SD 9.23). 73 
patients had ongoing sputum purulence and/or Anthonisen type 1 and/or a raised 
CRP.
Primary endpoint 
At 90 days after commencing retreatment, 41 (56.9%) patients in the ciprofloxacin 
and 38 (52.8%) in the placebo group had experienced 1 or more exacerbations. The 
median time to the first exacerbation in the ciprofloxacin group was 34 days (IQR 17-
62) and 32 days (IQR 13-50) in the placebo group. There was no significant 
difference between treatment arms in a pre-specified Cox proportional hazard model 
analysis that adjusted for the number of exacerbations in the previous year and 
stratified by centre (HR = 1.071, 95%CI 0.684-1.676, p=0.764; Figure 3). Patients 
with a prior history of more exacerbations in the previous year were at greater risk of 
another event (HR = 1.18, 95%CI 1.060-1.319; p=0.003).
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Subgroup analyses
The primary outcome findings were unchanged if only those exacerbations included 
for reasons of persistent respiratory symptoms were examined, or only those with a 
raised CRP at 14 days (see table 2).  
There was a significant difference between the two major recruitment sites (Royal 
Brompton, London (n=106) and Aintree, Liverpool (n=25), with a greater risk of a 
subsequent exacerbation at Aintree (hazard ratio=2.14; p=0.006).
Secondary endpoints
Duration of symptoms post-randomisation
Data was available on 113 patients (78%); 25 participants failed to adequately 
complete diary cards and 6 participants continually recorded chronic symptoms. The 
median number of days symptoms persisted after retreatment was 3 days (IQR 0-8, 
n=56) for ciprofloxacin, and 4 days (0-9, n=57) for placebo; Mann-Whitney p=0.703).
Exacerbation rate during follow up 
Over 90 days, there were slightly more exacerbations (median 1 (IQR 0-1); mean = 
0.86 (SD 0.91) in the ciprofloxacin group compared to (median 1 (IQR 0-1); mean = 
0.74 (SD 0.90) in the placebo group. In an unadjusted analysis, there was no 
difference in the exacerbation rate between the two arms, with an incident rate ratio 
for ciprofloxacin compared to placebo of 1.14 (95% CI: 0.78-1.66; p=0.498).
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Lung function changes
There were no significant between-group differences in the change in FEV1, FVC or 
FEV1/FVC ratio at any time point (figure 4 and supplementary table 2). Once data 
collected post-second exacerbation (occurring in the 90 day study period) were 
excluded, significant improvements were seen in FEV1 and FVC, but not FEV1/FVC 
ratio, in both treatment groups following the index exacerbation (supplementary 
figure 4). However,  there were  no significant differences between treatment groups 
in this analysis. 
Quality of life questionnaire assessments
Comparing treatment arms, there was no difference in change in total or component 
SGRQ scores between randomisation and day 90. (Table 3). The CAT scores also 
did not differ comparing ciprofloxacin and placebo (0.77 higher for ciprofloxacin 
versus placebo 95% CI: -1.71 to 3.27; p=0.540) (figure 5). 
C-reactive protein
CRP was significantly lower at V2 and V3 than at randomisation but there were no 
differences between treatment groups. All 144 exacerbations were treated with 
antibiotics; 117 were also treated with oral prednisolone and 27 with antibiotics 
alone. The prednisolone-treated exacerbations had a CRP of 8 mg/dL (IQR 3-20; 
n=26) compared to 7.8 mg/dl (IQR 3-9.9, n=115) forthe antibiotic-only treated 
exacerbations (Mann-Whitney; p=0.35). CRP was not recorded for 3 exacerbations.
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Index exacerbation characteristics CAT, CRP and bacterial culture.
At randomisation 46/144 subjects (31.9%) provided sputum for bacterial culture, 
which yielded a positive result in 45.7%. Ciprofloxacin resistant organisms were not 
present in sputum cultures subsequently collected from any participants receiving 
ciprofloxacin (table 4 and 5).
Adverse events
Two patients, one from each treatment arm, died within the 90-day follow-up window, 
one from an AECOPD and one from bowel ischaemia and multi organ failure; these 
deaths were not considered to be related to the trial interventions (Table 7). During 
the 90 days of follow-up, 5 of 72 patients (6.9%) with available data in the 
ciprofloxacin group and 6 of 72 (8.3%) patients with available data in the placebo 
group were hospitalised. 
There were no clinically important between-group differences in adverse events 
(Table 6 and 7).
Discussion
This is the first study to examine retreatment with antibiotics of incompletely 
recovered AECOPD. We observed no effect of retreatment with ciprofloxacin 
compared to placebo on the primary outcome of time to the next exacerbation. There 
were also no effects on lung function, quality of life, CRP, or the duration of 
symptoms following the index exacerbation. The intervention was well tolerated, with 
no significant differences in the frequency of adverse events.
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Although most COPD exacerbations last for approximately 10 days, some may last 
longer and at 5 weeks, 25% may not have fully recovered (10). Another feature of 
COPD exacerbations is the increased risk of developing another exacerbation within 
an eight week period (9, 14), and we have previously reported that a raised serum C-
Reactive Protein (CRP) concentration measured 14 days after a first exacerbation is 
predictive of a second, suggesting that failure to normalise the inflammatory 
response may predispose to another (recurrent) exacerbation (14).  Exacerbations 
are associated with heterogeneous inflammatory processes, mainly neutrophilic, and 
usually triggered by respiratory viral infections followed by secondary bacterial 
infection (18) (19). or primary bacterial infection.  For these reasons we aimed in this 
study to test an innovative approach to the use of antibiotics in preventing recurrent 
COPD exacerbations: the targeted re-treatment of patients following a first 
exacerbation who have incomplete symptom or inflammatory recovery.
The lack of an effect of ciprofloxacin in this trial would suggest that by day 14, these 
persistent symptoms and elevated CRP are driven predominantly by residual airway 
inflammatory load without a significant bacterial infective component, and this is 
reinforced by the low rates of bacterial sputum culture positivity in these patients. 
Further studies are required to study mechanisms of exacerbation recovery so that 
potential anti-inflammatory therapies can be targeted. A recent study reported the 
use of oral macrolides at hospitalization and continuing for 3 months after discharge 
(20, 21). Despite the trial under-recruiting, a trend favoured the azithromycin 
intervention over placebo in preventing subsequent AECOPD (treatment failure 49% 
versus 60% p=0.0526). Taking our observations into account, this finding could be 
the result of anti-inflammatory immunomodulatory effects of macrolides rather than 
antimicrobial action (22). 
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Time to next exacerbation is a commonly used outcome measure in clinical trials 
(23). All exacerbations were moderate to severe with many treated or hospitalized by 
independent physicians. The CAT scores and CRP concentrations of patients when 
they initially presented with exacerbation were similar to those reported at 
exacerbation presentation in other studies.(20, 24, 25). The retreatment antibiotic, 
ciprofloxacin, was selected as a reasonable second line antibiotic choice based on 
global guidelines for bacterial respiratory infection (16, 26, 27). It is important to 
acknowledge that the dose selected was not optimized to cover for active 
pseudomonas infection (usually 750mg/12 h for 14 days). However, we observed 
that only 3.5% (5 participants) yielded a positive bacterial culture for Pseudomonas, 
suggesting this was not a major contributor to re-exacerbation. It is also possible that 
the immunomodulatory effects of macrolides would have had more effect. The 
recruitment target was met but even if the sample size had been larger it is unlikely 
that a beneficial effect would have been detected. Importantly the observed rate of a 
subsequent exacerbation was lower than anticipated by the power calculation. Our 
study anticipated a large effect size (HR 0.46) which we felt would be meaningful to 
patients but created the possibility of type II error, or failure to detect a smaller 
beneficial effect of retreatment, when a beneficial effect exists. However, the study 
recruited to target and the absence of any trend favouring treatment makes this less 
likely. It is possible that a divergence in outcome between the ciprofloxacin and 
placebo group might have developed had the participants been followed  for 12 
months rather than  the 90 days we specified. However, previous work from our 
group suggested that   a further  exacerbation occurred in 36% of cases by 50 
days(14). Furthermore, patients were recruited from emergency and outpatient clinic 
departments rather than an established longitudinal cohort and so commitment to a 
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12-month follow up period could have increased the difficulty of recruitment. Thus 90 
days was considered a reasonable length of time to expect individuals to participate 
and mitigate the loss to follow up.
We chose CRP as a familiar clinical parameter that can be measured with a 
relatively inexpensive point-of-care device. The utility of point-of-care testing in the 
context of AECOPD is also emerging. Butler and colleagues show that at AECOPD 
onset a rapid detection of CRP can successfully rationalise antibiotic use (15). 
Instead we have used point-of-care CRP testing at day 14 to assess non-recovery. 
However, CRP cannot distinguish between a bacterial and viral triggered 
exacerbation. Around half of all AECOPD are triggered by respiratory viruses (22-
64%) particularly human rhinovirus (28). Empirical antibiotics do still offer a benefit 
(7), as recent work suggests that rhinovirus directly influences the lung’s innate 
immunity to impair bacterial phagocytosis allowing bacterial outgrowth (28, 29). 
Spirometry data collected at the V2-V4 time-points may have been influenced by 
secondary exacerbations. However, once lung function collected after a second 
exacerbation within the 90 day study period were excluded, significant improvements 
were seen in FEV1 and FVC, but not FEV1/FVC ratio, in both treatment groups 
following the index exacerbation.  This is in line with exacerbation recovery but there 
were no significant differences between treatment groups.
Another approach to improving the targeted retreatment would be to obtain bacterial 
sputum culture, though as observed in our study, and by others with a similar cohort 
demographic (20), many patients do not spontaneously expectorate 14 days after an 
index exacerbation. In our study only 44 individuals (31.9%) were able to provide 
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sputum, and a bacterial positive yield was obtained in 18.7% (20.8% active, 16.6% 
placebo).
During recruitment for this study, 38/80 (48%) patients were excluded at the 
screening visit because they had recovered. This fits with our understanding of the 
normal time-course of AECOPD (10). However, a notable finding was that 29% of 
individuals identified as suitable for the study were excluded because they had 
already commenced antibiotic retreatment prior to screening at day 14. This 
suggests that a sizable subpopulation of AECOPD experience treatment failure or 
require treatment intensification, a step-up in hospital care or readmission early. The 
results of this study would suggest that there is scope to reduce unnecessary 
antibuiotic retreatment. 
The strengths of this study were that it was multi-centre and met the pre-specified 
recruitment target. We also found that the duration of symptoms post-randomisation 
as one of our secondary outcomes could not be determined easily because patients 
poorly recorded symptoms on the diary cards. Of the 144 participants, 43 did not 
record any increase in symptoms on day 1 and day 2 post-randomisation, 6 patients 
continuously recorded symptoms during the whole follow-up period, and 25 
participants never recorded any symptoms. This was surprisingly poor compliance 
compared to our experience with the London COPD cohort and could be explained 
by inexperience with the daily diary cards, as well as being a post-exacerbation 
rather than stable cohort. 
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Conclusion
This randomized, placebo control trial found no benefit of treatment with ciprofloxacin 
of exacerbations with persistent respiratory symptoms or a raised CRP (>=8 mg/dl) 
at 14 days post exacerbation onset. This suggests that non-recovered exacerbations 
which may lead to hospital readmission potentially need to be targeted with anti-
inflammatory therapies and further research is now warranted to investigate 
exacerbation recovery.
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Tables/Figures
Figure 1 – The trial study design. 
Abbreviations: COPD,chronic obstructive pulmonary disease; V1, visit 1; V2, visit 2;
 V3, visit 3; V4, visit 4. 
Page 26 of 45
 AJRCCM Articles in Press. Published April 08, 2020 as 10.1164/rccm.201910-2058OC 
 Copyright © 2020 by the American Thoracic Society 
Figure 2 - Consolidated Standards of Reporting Trials Diagram of the Targeted 
Retreatment of Exacerbations in COPD: A Double blind, Randomised, Placebo-
controlled, Multicentre Phase III Trial.
Abbreviations: IMP, Investigational medicinal product. 
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Figure 3 - Kaplan-Meier survival estimate demonstrating the primary endpoint - 
proportion of patients free from exacerbation.
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Figure 4 – Effect of the intervention on change in spirometry by treatment 
group. A-C demonstrates the change in FEV1, FVC and FEV1/FVC ratio 
respectively. 
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity. 
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Figure 5 – Effect of the intervention on change in CAT Score by treatment 
group.  Demonstrating the effect of the intervention on change in CAT score by 
treatment group. 
Abbreviations: CAT, COPD assessment test. 
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Age - years 69.1 (8.8) 69.1 (7.4) 1.000
Weight – kg 77.4 (16.5) 77.1 (21.0) 0.909
Height - m 1.68  (0.11) 1.70 (0.09) 0.295
BMI 27.5 (5.8) 26.5 (6.0) 0.312
Males – n (%) 44 (61.1) 47 (65.2) 0.604
Current Smoker - n 24 26 0.726




3 (1-4) 2 (1-4) 0.879
Anthonisen 
Criteria
Type I 11 11 0.763
Type II 15 19 0.467
Type III 31 32 0.859
Examination 
findings
FEV1 - litres 1.29 (0.52) 1.38 (0.51) 0.269
FEV1 - % predicted 48.7 (16.5) 50.0 (14.9) 0.608
FVC - litres 2.79 (0.89) 2.91 (0.76) 0.380
FEV1/FVC 0.47 (0.14) 0.48 (0.13) 0.734
Oxygen Sats - % 94.8 (2.24) 95.0 (1.97) 0.555
Resp. Rate 17.4 (2.7) 17.8 (2.8) 0.322
Point of Care Sampling
CRP 15.2 (12.2) 19.9 (16.3) 0.158
Disease Burden 
Questionnaires
SGRQ Total 53.4 (18.1) 52.4 (17.2) 0.732
CAT 21.1 (8.3) 19.8 (7.7) 0.324
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Table 1 – Characteristics of patients at randomisation, by treatment group
Abbreviations: kg, kilograms; BMI, body mass index; IQR, interquartile range; 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; CRP, C-
reactive protein; SGRQ, St Georges Respiratory Questionnaire; CAT, COPD 
assessment test. 
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Reason for inclusion Haz. Ratio Lower CI Upper CI p-value
Persistent symptoms 
(n=128) $
1.167 0.734 1.856 0.513
CRP >=8 mg/dl
(n=64)
0.968 0.480 1.952 0.928
No persistent symptoms 
but only CRP >=8 mg/dl
(n=16)
0.667 0.073 6.06 0.719
Table 2 – Characteristics of patients at randomisation, by treatment group
Abbreviations: CRP, C-reactive protein.
$ Those with persistent symptoms included 48 participants whose CRP exceeded or 
was equal to 8 mg/dl
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SGRQ Total - Placebo 52.4 (17.2) 47.8 (16.0) -3.37 (11.5)
SGRQ Total - Cipro 53.4 (18.1) 50.5 (17.8) -1.93 (9.1) 0.440
SGRQ Impact - Placebo 40.8 (20.0) 38.5 (18.4) -1.97 (12.8)
SGRQ Impact - Cipro 39.0 (20.0) 35.8 (17.8) -0.74 (10.8) 0.560
SGRQ Activity - Placebo 68.2 (21.8) 65.1 (20.2) -1.74 (17.1)
SGRQ Activity - Cipro 67.3 (21.7) 67.8 (22.5) 1.17 (12.8) 0.283
SGRQ Symptoms - Placebo 66.4 (15.3) 54.3 (19.3) -11.3 (20.1)
SGRQ Symptoms - Cipro 68.9 (16.6) 55.7 (22.0) -11.5 (21.5) 0.949
Table 3 - Demonstrates the changes in total as well as the impact, activity and 
symptom subsections of the SGRQ score between visit 1 and 4. 
Abbreviations: Cipro, ciprofloxacin; SGRQ, St Georges Respiratory Questionnaire.
Page 34 of 45
 AJRCCM Articles in Press. Published April 08, 2020 as 10.1164/rccm.201910-2058OC 
 Copyright © 2020 by the American Thoracic Society 










CRP Placebo 15.1 (17.2) 11.0 (17.2) 9.8 (17.7) 9.0 (15.2)
CRP Ciprofloxacin 10.9 (12.3) 9.8 (13.1) 7.0 (17.7) 15.2 (46.9)








CRP Placebo -5.1 (22.1) -5.3 (17.0) -6.4 (20.1)
CRP Ciprofloxacin -1.7 (14.7) -4.6 (12.4) 3.9 (48.0)
p-value (t-test) 0.310 0.815 0.124
Median (IQR)  
CRP Placebo -2 (-13 to 0) -1.75 (-9 to 
0.1)
-2 (-11.5 to 1)
CRP Ciprofloxacin 0 (-5 to 2) -1 (-5 to 1) -1 (-4 to 0)
Mann-Whitney 0.030 0.741 0.195
Table 4 - compares the changes in CRP seen in the ciprofloxacin and placebo 
groups at study visits.
Abbreviations: CRP, C-reactive protein; IQR, interquartile range.
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Ciprofloxacin Placebo
Baseline N= % N= %
Number of patients with a 
sputum sample
25 (34.7) 22 (30.5)
Number bacterial cultures 
positive for a pathogen
15  (20.8) 12 (16.6)
     Haemophilus influenzae 6 (8.3) 4 (5.5)
     Streptococcus pneumoniae 1 (1.4) 2 (2.8)
     Pseudomonas aeruginosa 2 (2.8) 3 (4.2)
     Morexella catarrhalis 3 (4.2) 1 (1.4)
     Staphylococcus aureus 0 1 (1.4)
     Other gram-negative bacteria 3 (4.2) 1 (1.4)
Cultures with ciprofloxacin 
resistant bacteria 
1 (1.4) 0 
Day 90
Number of patients with a 
sputum sample
16 (22.2) 17 (23.6)
Number bacterial cultures 
positive for a pathogen
7  (9.7) 7 (9.7)
Number with newly acquired 
ciprofloxacin resistance
0 1 (1.4)
Table 5 - Summary of spontaneous sputum samples bacterial cultures
Brackets indicate % unless otherwise specified.
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Dyspepsia 1 0 
Abdominal colic/Pain 2 2 
Miscellaneous 
Pruritis/Rash 0 2
Dry mouth 1 0
Ankle pain/tendinitis 2 0
Tremor 0 1
Table 6 - Summary of study adverse events
Brackets indicate % unless otherwise specified.
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Table 7 - Summary of study adverse events
Brackets indicate % unless otherwise specified.
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List of study sites
Recruitment site Participants (n=144)
Royal Brompton and Harefield NHS Trust 106
Aintree University Hospital NHS Foundation 
Trust
25
St Mary’s Hospital, Imperial College 
Healthcare NHS Trust
8
St George’s University Hospitals NHS Trust 5
Table 1 - Summary of recruited subjects by site to the Targeted 
Retreatment of Incompletely Recovered COPD Exacerbations with Ciprofloxacin 
trial. 
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No of Exacerbations over follow-up (90 days)
Graphs by Randomised group
Figure 1 - Distribution of exacerbation frequencies in the two arms of the study. 
Exacerbations frequency was similar in both treatment arms (p=0.498).
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Figure 2 – Effect of the intervention on change in C-reactive protein. A 
demonstrates the effects on CRP. B examines the effect of the intervention on 
changes in CRP by treatment group. Day 0 represents the randomization visit. 
Abbreviations: CRP, C-reactive protein; mg, milligrams; dL, decilitres. 
Figure 3 – Effect of the intervention on change in CAT Score by treatment 
group. Examining the change in CAT score by treatment group when secondary 
exacerbation data is excluded. Day 0 represents the randomization visit. 
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Figure 4 – Effect of the intervention on change in spirometry by treatment 
group. A-C examines changes in lung function when secondary exacerbation data is 
excluded. 
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Inclusion and Exclusion criteria
Inclusion Criteria: 
 Diagnosis of COPD confirmed spirometrically at screening
 COPD exacerbation with treatment commenced 14 days prior to study 
enrolment and treated with 5-14 days of a non-quinolone antibiotic. 
Exacerbation here will be defined as an episode of symptomatic worsening of 
COPD that was treated by the patient’s attending clinician. Confirmation of the 
initial exacerbation diagnosis will be provided from the case notes, referral 
letter, or directly from the treating clinician, and will be documented in the 
CRF. 
 Age: ≥ 45 years of age at screening.
 Persistent symptoms and/or a CRP≥8mg/L when assessed 2 weeks after 
exacerbation onset
 Able to complete questionnaires for health status and symptoms and keep 
written diary cards
 Severity of disease: Patients with a measured FEV1<80% of predicted normal 
values at 2 weeks post exacerbation 
 Able and willing to give signed and dated written informed consent to 
participate
Exclusion Criteria: 
 Other clinically predominant chronic respiratory disease. 
 Intubated and receiving mechanical ventilation 
 Patients with known hypersensitivity to the antibiotic under evaluation, to other 
quinolones or any excipients of the IMP/placebo.
 Patients with a prior history of tendinopathy or tendon rupture
 Elderly patients taking long term systemic corticosteroids
 Patients on long term antibiotics for other conditions
 Patient too unwell for randomisation, i.e. requiring retreatment in the judgment 
of the study doctor
 Female patients who are pregnant or planning on becoming pregnant during 
the study, or are breastfeeding.  
 Patient taking clinically significant contraindicated medication as per the 
SmPC s, such as use of concomitant tizanidine or methotrexate.
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Ciprofloxacin Placebo
Baseline
N=72 Ciprofloxacin; 72 Placebo
FEV1 1.29 (0.52) 1.38 (0.51)
FVC 2.79 (0.89) 2.91 (0.76)
FEV1/FVC ratio 47.2 (13.8) 47.9  (13.2)
Day 7
N=68 Ciprofloxacin; 67 Placebo
FEV1 1.31 (0.49) 1.37 (0.53)
FVC 2.87  (0.90) 2.87 (0.79)
FEV1/FVC ratio 47.4 (14.1) 48.0 (13.8)
Day 28
N=64 Ciprofloxacin; 62 Placebo
FEV1 1.31 (0.49) 1.37 (0.52)
FVC 2.85  (0.82) 2.90 (0.91)
FEV1/FVC ratio 47.0 (14.4) 47.9 (13.2)
Day 90
N=63 Ciprofloxacin; 63 Placebo
FEV1 1.36 (0.51) 1.37 (0.55)
FVC 2.95 (0.86) 2.96 (0.93)
FEV1/FVC ratio 47.4 (14.8) 46.9 (13.6)
Table 2 - shows means (SD), and number of patients measured. The number of 
measurement decreased in both the placebo and ciprofloxacin groups as participant 
withdrew from the study.
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